BiOPTiK TECHNOLOGY, INC. Outlook Dec Listed Number:4161

Transcription

1 BiOPTiK TECHNOLOGY, INC. Outlook Dec Listed Number:4161

2 Briefing content Corporate Introduction Product and Forecast Performance Introduction Quality System Headquarter Medical Device Hsinchu Science Park Branch Office/ Factory Cosmetics and Dietary Supplements Tainan Branch Natural Astaxanthin Financial Highlights Sales Breakdown by Region Sales Breakdown by Product Dividend Policy

3 Corporate Introduction Date of Establishment: June 1 st, 1999 Entity: Incorporation Listing IPO: June, 2011 July, 2011 at emerging stock market June, 2013 OTC-listed; list number: 4161 Product Category: Medical Device, Medical In Vitro Diagnostic Device, Cosmetics, Dietary Supplements, Natural Astaxanthin

4 Quality System ISO GMP(Good Manufacturing Practice in Taiwan) Product: CE IVD(European Union), FDA(USA), SFDA(China) approved, Health dept of Taiwan passed. ISO 9001; ISO 22716;ISO22000;HACCP ;ISO13485

5 Hsinchu Science Park Branch Office Headquarter Tainan Branch

6 Headquarter Medical Device and Medical In Vitro Diagnostic Device G Blood Glucose Monitoring System GU Blood Glucose/ Uric Acid Dual Function Monitoring System GC Blood Glucose/ Cholesterol Dual-function Monitoring System GCU Blood Glucose/ Cholesterol/ Uric Acid Multifunction Monitoring System GCHb Blood Glucose/ Cholesterol/ Hemoglobin Multifunction Monitoring System BPGC Blood Pressure/ Glucose/ Cholesterol Multifunction Monitoring System

7 Highlights - IoT Applications Monitoring System Connects to Mobile Device Monitoring System Connects to Mobile Device Monitoring System Connects to Tablet Monitoring System Connects to Tablet Barcode Application Data Transmission Data Management POCT Health System

8 Headquarter Forecast IoT Long-term Care Platform Human Resourc e System Healthcar e System Social Work System Genera l Affairs System Long-term Care System Professional Healthcare System Indicator Monitoring System Vital Value System transdisciplinary System

9

10 Hsinchu Science Park Branch Cosmetics and Dietary Supplements ACUREAL Product Series Medical Grade Scar Gel Natural Astaxanthin Dietary Supplements Scar therapy gel 3M Far Yea Product Series

11 Hsinchu Science Park Branch Launch New Dietary Supplement Products

12 Hsinchu Science Park Branch Forecast Effective Efficient Cosmetics Dietary Supplements Blood Lipids Modulation Wellness Scar Care Wound Care Medical Device

13 Hsinchu Science Park Branch Forecast Complete Wound Care Haemos tatic Wound Dressing Natural biomaterials Stop bleeding in 30 seconds Liquid Wound Dressing(St erile) Improve wound healing Reducing pain during wound dressing changes Scar Gel Scar care Minimal irritation and transparent Acureal Product Clo-Sur PAD Instant Clot Pad Hemostatic dressing absorption test Liquid Wound ressing(sterile) cell proliferation test Scar gel clinical evaluation

14 Tainan Branch Natural Astaxanthin Medical grade/ free-state astaxanthin (98%) As a mega antioxidant, it slows down the oxidation reaction to eliminates the chain reaction of free radicals, hence to protect cells against oxidation. Highly purified medical grade free-state astaxanthin can be used as supplement to traditional therapy. Marketing: medical supplement, laboratory reference material Food grade/ free-state astaxanthin (2%) Protect cells against oxidatio with antioxidant property. With the benefits of antioxidant property to eliminate free radical, it can serve as dietary supplement with compound substances for additive effect, such as promoting eye health and immunity, preventing of atherosclerosis cardiovascular diseases. Marketing: Dietary supplement additives Feed/ ester-state astaxanthin (2%) Egg yolk coloring and add antioxidant benefit as additive value Coloring on aquatic livestock to elevate marketing value Promote gonadal gland health and increase conception rate Increase cell membrane elasticity and resistance Marketing: aquaculture and livestock feed additive

15 Tainan Branch Forecast Abstraction/ purification Microencapsulation Class 3 registration (registered) Efficacy Evaluation Human Daily Dosage: 6mg/60kg B.W. Chemical liver damage treatment evaluation (M ) Ethanol liver damage treatment evaluation (I-Shou University/ Department of Biomedical Engineering) Cholesterol induced fatty liver treatment evaluation (journal.pone ) Safety Evaluation Salmonella reverse mutation test (M ) Micronuclei in peripheral blood of rodents Chromosomal aberration test with mammalian cells in culture Teratogenicity 90-day feeding toxicity study Astaxanthin Stability Evaluation Human Daily Dosage: 80mg/60kg B.W. PTP (10 piece/ tablet) 6 month accelerated test/ 40 C 75% R.H. (M R01)

16 In Vivo Effects of Astaxanthin In Vivo Effects of Free Form Astaxanthin Powder on Anti-Oxidation and Lipid Metabolism with High-Cholesterol Diet Published: August 11, 2015https://doi.org/ /journal.pone

17 Carbon trtrachloride-induced severe liver fibrosis chemical liver damage treat with Astaxanthin (Report number: M )

18 Ethanol-induced severe liver fibrosis - alcohol-induced liver damage treat with Astaxanthin (I- Shou University/ Department of Biomedical Engineering) Normal mouse liver Alcohol-induced liver damage Oral Astaxanthin treatment Intraperitoneal injection Astaxanthin treatment Normal liver dissection Damaged liver dissection liver fibrosis Liver dissection after oral treatment Liver dissection after injection treatment * Alcohol-induced liver damage animal model shows the effectiveness of astaxanthin treatment according to the liver dissection. Injection method is superior than oral dosage treatment according to the experiment conducted.

19 Astaxanthin Feed Highlight Aquaculture livestock breeding coloring

20 Benefit and Value Applications Safety, efficacy, stability testing and dosage form development completed Class 3 health food certified and Launch The new plant was officially operatred; extraction, purification and application developments are completed and are the front runner 完成第一軌 個案審查 第三類 護肝 健康食品認證 Astaxanthin feed additives launch to the market and increases revenue.

21 Financial Highlights consolidated statement Year Q3 Revenue 451, , , , ,321 Margin 129, , , ,581 79,342 Operating Profit 49,404 26,668 55,731 17,726 (4,467) Net Income before tax 85,494 35,744 40,270 9,480 (34,775) EPS (0.53) Gross Profit Margin 29% 28% 36% 29% 22% Operating Profit Margin 11% 6% 12% 4% -1% Net Profit Margin 19% 9% 9% 2% -10%

22 Sales Breakdown by Region 100% 95% 11% 12% 12% 13% 14% 90% 85% 80% 75% Other Region Taiwan 70% 89% 88% 88% 87% 86% 65% 60% 55% 50% Q3

23 Sales Breakdown by Product 100% 0% 0% 0% 0% 0% 5% 4% 6% 5% 5% 95% 90% Others 85% 95% 94% 96% 94% 95% Cosmetics IVD Products 80% 75% 70% Q3

24 Dividend Policy Year EPS Cash DPS Stock DPS Dividend Payout Ratio 93.75% 0.00% 68.49% % 91.07% %

25 Q & A

26 An industry that creates healthy, beautiful and environmentally friendly product BiOPTiK TECHNOLOGY, INC. Thank you for listening~